Search

Your search keyword '"Bunse, Theresa"' showing total 20 results
Start Over Author "Bunse, Theresa" Search Limiters Full Text Publication Year Range Last 50 years
20 results on '"Bunse, Theresa"'

1. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

Author

Grassl, Niklas, Sahm, Katharina, Süße, Heike, Poschke, Isabel, Bunse, Lukas, Bunse, Theresa, Boschert, Tamara, Mildenberger, Iris, Rupp, Anne-Kathleen, Ewinger, Max Philipp, Lanz, Lisa-Marie, Denk, Monika, Tabatabai, Ghazaleh, Ronellenfitsch, Michael W., Herrlinger, Ulrich, Glas, Martin, Krex, Dietmar, Vajkoczy, Peter, Wick, Antje, Harting, Inga, Sahm, Felix, von Deimling, Andreas, Bendszus, Martin, Wick, Wolfgang, and Platten, Michael

Published
2023
Full Text
View/download PDF

2. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Author

Turco, Verena, Pfleiderer, Kira, Hunger, Jessica, Horvat, Natalie K., Karimian-Jazi, Kianush, Schregel, Katharina, Fischer, Manuel, Brugnara, Gianluca, Jähne, Kristine, Sturm, Volker, Streibel, Yannik, Nguyen, Duy, Altamura, Sandro, Agardy, Dennis A., Soni, Shreya S., Alsasa, Abdulrahman, Bunse, Theresa, Schlesner, Matthias, Muckenthaler, Martina U., Weissleder, Ralph, Wick, Wolfgang, Heiland, Sabine, Vollmuth, Philipp, Bendszus, Martin, Rodell, Christopher B., Breckwoldt, Michael O., and Platten, Michael

Published
2023
Full Text
View/download PDF

4. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Author

Bunse, Lukas, Rupp, Anne-Kathleen, Poschke, Isabel, Bunse, Theresa, Lindner, Katharina, Wick, Antje, Blobner, Jens, Misch, Martin, Tabatabai, Ghazaleh, Glas, Martin, Schnell, Oliver, Gempt, Jens, Denk, Monika, Reifenberger, Guido, Bendszus, Martin, Wuchter, Patrick, Steinbach, Joachim P, Wick, Wolfgang, and Platten, Michael

Published
2022
Full Text
View/download PDF

5. A vaccine targeting mutant IDH1 in newly diagnosed glioma

Author

Platten, Michael, Bunse, Lukas, Wick, Antje, Bunse, Theresa, Le Cornet, Lucian, Harting, Inga, Sahm, Felix, Sanghvi, Khwab, Tan, Chin Leng, Poschke, Isabel, Green, Edward, Justesen, Sune, Behrens, Geoffrey A., Breckwoldt, Michael O., Freitag, Angelika, Rother, Lisa-Marie, and Schmitt, Anita

Subjects
Gliomas -- Genetic aspects -- Care and treatment, Vaccines -- Testing, Oxidoreductases -- Physiological aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma.sup.1-3. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II.sup.4,5. An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H).sup.+ tumours in syngeneic MHC-humanized mice.sup.4,6-8. Here we describe a multicentre, single-arm, open-label, first-in-humans phase I trial that we carried out in 33 patients with newly diagnosed World Health Organization grade 3 and 4 IDH1(R132H).sup.+ astrocytomas (Neurooncology Working Group of the German Cancer Society trial 16 (NOA16), ClinicalTrials.gov identifier NCT02454634). The trial met its primary safety endpoint, with vaccine-related adverse events restricted to grade 1. Vaccine-induced immune responses were observed in 93.3% of patients across multiple MHC alleles. Three-year progression-free and death-free rates were 0.63 and 0.84, respectively. Patients with immune responses showed a two-year progression-free rate of 0.82. Two patients without an immune response showed tumour progression within two years of first diagnosis. A mutation-specificity score that incorporates the duration and level of vaccine-induced IDH1(R132H)-specific T cell responses was associated with intratumoral presentation of the IDH1(R132H) neoantigen in pre-treatment tumour tissue. There was a high frequency of pseudoprogression, which indicates intratumoral inflammatory reactions. Pseudoprogression was associated with increased vaccine-induced peripheral T cell responses. Combined single-cell RNA and T cell receptor sequencing showed that tumour-infiltrating CD40LG.sup.+ and CXCL13.sup.+ T helper cell clusters in a patient with pseudoprogression were dominated by a single IDH1(R132H)-reactive T cell receptor. A phase 1 clinical trial provides evidence that a vaccine against mutant IDH1 is safe and produces a T helper immune response in patients with glioma., Author(s): Michael Platten [sup.1] [sup.2] [sup.3] , Lukas Bunse [sup.1] [sup.2] , Antje Wick [sup.4] [sup.5] , Theresa Bunse [sup.1] [sup.2] , Lucian Le Cornet [sup.6] , Inga Harting [sup.7] [...]

Published
2021
Full Text
View/download PDF

6. A Cellular Ground Truth to Develop MRI Signatures in Glioma Models by Correlative Light Sheet Microscopy and Atlas-Based Coregistration

Author

Schregel, Katharina, primary, Heinz, Lennart, additional, Hunger, Jessica, additional, Pan, Chenchen, additional, Bode, Julia, additional, Fischer, Manuel, additional, Sturm, Volker, additional, Venkataramani, Varun, additional, Karimian-Jazi, Kianush, additional, Agardy, Dennis A., additional, Streibel, Yannik, additional, Zerelles, Roland, additional, Wick, Wolfgang, additional, Heiland, Sabine, additional, Bunse, Theresa, additional, Tews, Björn, additional, Platten, Michael, additional, Winkler, Frank, additional, Bendszus, Martin, additional, and Breckwoldt, Michael O., additional

Published
2023
Full Text
View/download PDF

7. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

Author

Bunse, Lukas, Pusch, Stefan, Bunse, Theresa, Sahm, Felix, Sanghvi, Khwab, Friedrich, Mirco, Alansary, Dalia, Sonner, Jana K., Green, Edward, Deumelandt, Katrin, Kilian, Michael, Neftel, Cyril, Uhlig, Stefanie, Kessler, Tobias, von Landenberg, Anna, Berghoff, Anna S., Marsh, Kelly, Steadman, Mya, Zhu, Dongwei, Nicolay, Brandon, Wiestler, Benedikt, Breckwoldt, Michael O., Al-Ali, Ruslan, Karcher-Bausch, Simone, Bozza, Matthias, Oezen, Iris, Kramer, Magdalena, Meyer, Jochen, Habel, Antje, Eisel, Jessica, Poschet, Gernot, Weller, Michael, Preusser, Matthias, Nadji-Ohl, Minou, Thon, Niklas, Burger, Michael C., Harter, Patrick N., Ratliff, Miriam, Harbottle, Richard, Benner, Axel, Schrimpf, Daniel, Okun, Jürgen, Herold-Mende, Christel, Turcan, Sevin, Kaulfuss, Stefan, Hess‐Stumpp, Holger, Bieback, Karen, Cahill, Daniel P., Plate, Karl H., Hänggi, Daniel, Dorsch, Marion, Suvà, Mario L., Niemeyer, Barbara A., von Deimling, Andreas, Wick, Wolfgang, and Platten, Michael

Published
2018
Full Text
View/download PDF

8. In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma

Author

Hunger, Jessica, primary, Schregel, Katharina, additional, Boztepe, Berin, additional, Agardy, Dennis Alexander, additional, Turco, Verena, additional, Karimian-Jazi, Kianush, additional, Weidenfeld, Ina, additional, Streibel, Yannik, additional, Fischer, Manuel, additional, Sturm, Volker, additional, Santarella-Mellwig, Rachel, additional, Kilian, Michael, additional, Jähne, Kristine, additional, Sahm, Katharina, additional, Wick, Wolfgang, additional, Bunse, Lukas, additional, Heiland, Sabine, additional, Bunse, Theresa, additional, Bendszus, Martin, additional, Platten, Michael, additional, and Breckwoldt, Michael O., additional

Published
2023
Full Text
View/download PDF

9. NIMG-41. NON-INVASIVE TRACKING OF T-CELL RECRUITMENT TO THE TUMOR MICROENVIRONMENT IN A MURINE GLIOMA MODEL BY HIGH FIELD CELLULAR MRI

Author

Hunger, Jessica, primary, Schregel, Katharina, additional, Fischer, Manuel, additional, Agardy, Dennis, additional, Sturm, Volker, additional, Karimian-Jazi, Kianush, additional, Bunse, Theresa, additional, Heiland, Sabine, additional, Wick, Wolfgang, additional, Bendszus, Martin, additional, Platten, Michael, additional, and Breckwoldt, Michael, additional

Published
2022
Full Text
View/download PDF

11. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma

Author

Friedrich, Mirco, primary, Hahn, Markus, additional, Michel, Julius, additional, Sankowski, Roman, additional, Kilian, Michael, additional, Kehl, Niklas, additional, Günter, Manina, additional, Bunse, Theresa, additional, Pusch, Stefan, additional, von Deimling, Andreas, additional, Wick, Wolfgang, additional, Autenrieth, Stella E, additional, Prinz, Marco, additional, Platten, Michael, additional, and Bunse, Lukas, additional

Published
2022
Full Text
View/download PDF

13. T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells

Author

Lu, Kevin Hai-Ning, primary, Michel, Julius, additional, Kilian, Michael, additional, Aslan, Katrin, additional, Qi, Hao, additional, Kehl, Niklas, additional, Jung, Stefanie, additional, Sanghvi, Khwab, additional, Lindner, Katharina, additional, Zhang, Xin-Wen, additional, Green, Edward W, additional, Poschke, Isabel, additional, Ratliff, Miriam, additional, Bunse, Theresa, additional, Sahm, Felix, additional, von Deimling, Andreas, additional, Wick, Wolfgang, additional, Platten, Michael, additional, and Bunse, Lukas, additional

Published
2022
Full Text
View/download PDF

15. NIMG-48. TLR7/8-AGONIST-LOADED NANOPARTICLES REPROGRAM TUMOR-ASSOCIATED MYELOID CELLS FOR EFFECTIVE IMMUNOTHERAPY OF EXPERIMENTAL GLIOMA AND MRI-BASED TREATMENT MONITORING

Author

Pfleiderer, Kira, primary, Turco, Verena, additional, Horvat, Natalie K, additional, Hunger, Jessica, additional, Karimian-Jazi, Kianush, additional, Schregel, Katharina, additional, Brugnara, Gianluca, additional, Nguyen, Duy, additional, Jähne, Kristine, additional, Fischer, Manuel, additional, Alsasa, Abdulrahman, additional, Bunse, Theresa, additional, Schlesner, Matthias, additional, Muckenthaler, Martina, additional, Weissleder, Ralph, additional, Wick, Wolfgang, additional, Heiland, Sabine, additional, Vollmuth, Philipp, additional, Bendszus, Martin, additional, Rodell, Christopher B, additional, Breckwoldt, Michael O, additional, and Platten, Michael, additional

Published
2021
Full Text
View/download PDF

16. IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING

Author

Friedrich, Mirco, primary, Bunse, Lukas, additional, Bunse, Theresa, additional, Green, Edward, additional, Kessler, Tobias, additional, Pusch, Stefan, additional, Carretero, Rafael, additional, Deimling, Andreas von, additional, Quintana, Francisco J, additional, Wick, Wolfgang, additional, and Platten, Michael, additional

Published
2018
Full Text
View/download PDF

17. ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS

Author

Platten, Michael, primary, Schilling, Daniela, additional, Bunse, Lukas, additional, Wick, Antje, additional, Bunse, Theresa, additional, Riehl, Dennis, additional, Green, Edward, additional, Sanghvi, Khwab, additional, Karapanagiotou-Schenkel, Irini, additional, Harting, Inga, additional, Sahm, Felix, additional, Steinbach, Joachim, additional, Weyerbrock, Astrid, additional, Hense, Jörg, additional, Misch, Martin, additional, Krex, Dietmar, additional, Stevanovic, Stefan, additional, Tabatabai, Ghazaleh, additional, von Deimling, Andreas, additional, Schmitt, Michael, additional, and Wick, Wolfgang, additional

Published
2018
Full Text
View/download PDF

18. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

Author

Blaes, Jonas, primary, Thomé, Carina M., additional, Pfenning, Philipp-Niclas, additional, Rübmann, Petra, additional, Sahm, Felix, additional, Wick, Antje, additional, Bunse, Theresa, additional, Schmenger, Torsten, additional, Sykora, Jaromir, additional, von Deimling, Andreas, additional, Wiestler, Benedikt, additional, Merz, Christian, additional, Jugold, Manfred, additional, Haberkorn, Uwe, additional, Abdollahi, Amir, additional, Debus, Jürgen, additional, Gieffers, Christian, additional, Kunz, Claudia, additional, Bendszus, Martin, additional, Kluge, Michael, additional, Platten, Michael, additional, Fricke, Harald, additional, Wick, Wolfgang, additional, and Lemke, Dieter, additional

Published
2018
Full Text
View/download PDF

19. K27M-mutant histone-3 as a novel target for glioma immunotherapy

Author

Ochs, Katharina, primary, Ott, Martina, additional, Bunse, Theresa, additional, Sahm, Felix, additional, Bunse, Lukas, additional, Deumelandt, Katrin, additional, Sonner, Jana K., additional, Keil, Melanie, additional, von Deimling, Andreas, additional, Wick, Wolfgang, additional, and Platten, Michael, additional

Published
2017
Full Text
View/download PDF

20. Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases.

Author

Gellert J, Agardy DA, Kumar S, Kourtesakis A, Boschert T, Jähne K, Breckwoldt MO, Bunse L, Wick W, Davies MA, Platten M, and Bunse T

Subjects
Animals, Mice, Humans, Phenotype, Tumor Microenvironment immunology, Tumor Microenvironment drug effects, Mice, Inbred C57BL, Female, Cell Line, Tumor, Brain Neoplasms secondary, Brain Neoplasms immunology, Interferon-beta, Tumor-Associated Macrophages immunology, Tumor-Associated Macrophages drug effects, Melanoma immunology, Melanoma pathology, Melanoma drug therapy, Melanoma secondary
Abstract

Type I interferons (IFN) are immune-stimulatory cytokines involved in antiviral and antitumor immune responses. They enhance the efficacy of immunogenic anticancer therapies such as radiotherapy by activating both innate and adaptive immune cells. Macrophages are one of the most abundant innate immune cells in the immune microenvironment of melanoma brain metastases (MBM) and can exert potent immune-suppressive functions. Here, we investigate the potential of tumoral type I IFNs to repolarize tumor-associated macrophages (TAM) in two murine MBM models and assess the effects of radiotherapy-induced type I IFN on TAMs in a transcriptomic MBM patient dataset. In mice, we describe a proinflammatory M1-like TAM phenotype induced by tumoral IFNβ and identify a myeloid type I IFN-response signature associated with a high M1/M2-like TAM ratio. Following irradiation, patients with MBM displaying a myeloid type I IFN-response signature showed increased overall survival, providing evidence that tumoral IFNβ supports an effective antitumor immune response by re-educating immune-regulatory TAM. These findings uncover type I IFN-inducing therapies as a potential macrophage-targeting therapeutic approach and provide a rationale for combining radiotherapy with concomitant immunotherapy to improve treatment response in patients with MBM., Significance: Our study shows that re-education of tumor-associated macrophages by tumoral IFNβ translates into improved clinical outcome in patients with melanoma brain metastases, providing pathomechanistic insights into synergistic type I interferon-inducing therapies with immunotherapies and warranting investigation of IFNβ as a predictive biomarker for combined radioimmunotherapy., (©2024 The Authors; Published by the American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results